Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Replicase polyprotein 1ab (2019-nCoV) | BDBM510127![]() (Methyl {(2S)-1-[(1R,2S,5S)-2-({(1S)-1-cyano-2-[(3S...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 1 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510063![]() (N-[(2S)-1-({(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin-3...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 2 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM496902![]() (PF-07321332 | WO2021250648, Example 13 | science.a...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | Purchase PC cid PC sid UniChem | WIPO | n/a | n/a | 3 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510127![]() (Methyl {(2S)-1-[(1R,2S,5S)-2-({(1S)-1-cyano-2-[(3S...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 3 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510132![]() ((1R,2S,5S)-N-{(1 S)-1-Cyano-2-[(3S)-2- oxopyrrolid...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 3 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510129![]() ((1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3R)-5-hydroxy-2-oxo...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 3 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510125![]() (3-Methyl-N-(trifluoroacetyl)-L-valyl-(4R)-N-{(1 S)...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 4 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510140![]() (3-Methyl-N-[(4-methylphenyl)acetyl]-L-valyl-(4R)-N...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 4 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510133![]() ((1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3R)-2,5-dioxopyrrol...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 4 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510126![]() ((1R,2S,5S)-N-{(1 S)-1-Cyano-2-[(3S)-2-oxopyrrolidi...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 5 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510068![]() (N-[(2S)-1-({(1 S)-1-Cyano-2-[(3S)-2-oxopyrrolidin-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 5 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510136![]() ((1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 6 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510137![]() ((1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 7 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510139![]() ((1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 7 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510145![]() ((1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 11 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510142![]() ((1R,2S,5S)-N-{(1 S)-1-Cyano-2-[(3S)-2-oxopyrrolidi...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 11 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510048![]() ((1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 13 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510141![]() ((1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 14 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510138![]() ((1R,2S,5S)-N-{(1 S)-1-Cyano-2-[(3S)-2-oxopyrrolidi...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 15 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510134![]() ((1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 16 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510123![]() ((2S,4R)-4-tert-Butyl-N-{(1S)-1-cyano-2-[(3S)-2-oxo...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 17 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510064![]() (N-[(2S)-1-({(1S)-1- Cyano-2-[(3S)-2-oxopyrrolidin-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 18 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510066![]() (N-[(2S)-1-({(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin-3...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 19 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510071![]() (N-[(2S)-1-({(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin-3...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 21 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510135![]() (WO2021250648, Example 87) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 21 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510086![]() (WO2021250648, Example 38) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 23 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510054![]() (N-[(2S)-1-({(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin-3...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 23 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510101![]() (WO2021250648, Example 53) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 25 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM496896![]() (WO2021250648, Example 4 | science.abl4784, 2) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 26 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510110![]() (WO2021250648, Example 62) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 29 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510100![]() (WO2021250648, Example 52) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 32 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510109![]() (WO2021250648, Example 61) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 34 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510128![]() (N-(Trifluoroacetyl)-L-valyl-(4R)-N-{(1S)-1-cyano-2...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 37 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510112![]() (WO2021250648, Example 64) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 38 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510115![]() (WO2021250648, Example 67) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 41 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510102![]() (WO2021250648, Example 54) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 49 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510105![]() (WO2021250648, Example 57) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 52 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510065![]() (N-[(2S)-1-({(1S)-1-Cyano-2-[(3S)-2- oxopyrrolidin-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 53 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM509871![]() (US11124497, Compound 405) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 56 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510070![]() (N-[(2S)-1-({(1 S)-1-Cyano-2-[(3S)-2- oxopyrrolidin...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 66 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510081![]() (WO2021250648, Example 33) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 68 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510114![]() (WO2021250648, Example 66) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 73 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510082![]() (WO2021250648, Example 34) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 74 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510117![]() (WO2021250648, Example 69) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 83 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM509848![]() (US11124497, Compound 361) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 83 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510106![]() (WO2021250648, Example 58) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 91 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510116![]() (WO2021250648, Example 68) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 92 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510131![]() ((1R,2S,5S,6S)-N-{(1S)-1-Cyano-2-[(3S)-2-oxopyrroli...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 92 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510089![]() (WO2021250648, Example 41) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 104 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510103![]() (WO2021250648, Example 55) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 104 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510087![]() (WO2021250648, Example 39) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 111 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510111![]() (WO2021250648, Example 63 | WO2021250648, Example 6...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 117 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510111![]() (WO2021250648, Example 63 | WO2021250648, Example 6...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 122 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510088![]() (WO2021250648, Example 40) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 131 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510130![]() ((1R,2S,5S,6R)-N-{(1 S)-1-Cyano-2-[(3S)-2-oxopyrrol...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 139 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510098![]() (WO2021250648, Example 50) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 147 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510104![]() (WO2021250648, Example 56) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 151 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510107![]() (WO2021250648, Example 59) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 152 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510085![]() (WO2021250648, Example 37) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 168 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510120![]() (WO2021250648, Example 72) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 173 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510083![]() (WO2021250648, Example 35) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 176 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510146![]() ((1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 188 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510099![]() (WO2021250648, Example 51) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 192 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510067![]() (N-[(2S)-1-({(1 S)-1-Cyano-2-[(3S)-2-oxopyrrolidin-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 208 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510121![]() (WO2021250648, Example 73) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 226 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510093![]() (WO2021250648, Example 45) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 227 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510084![]() (WO2021250648, Example 36) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 241 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510119![]() (WO2021250648, Example 71) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 254 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510057![]() (N-{1-Cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-N2-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 254 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510108![]() (WO2021250648, Example 60) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 261 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510094![]() (WO2021250648, Example 46) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 283 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510059![]() (N2-[(4-Bromo-1-ethyl-3-methyl-1H-pyrazol-5-yl)carb...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 297 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510062![]() (N-[(2S)-1-({(1 S)-1-Cyano-2-[(3S)-2-oxopyrrolidin-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 302 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510092![]() (WO2021250648, Example 44) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 302 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510053![]() (N-[(2S)-1-({(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin-3...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | >351 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510090![]() (WO2021250648, Example 42) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | >356 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510122![]() (WO2021250648, Example 74) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | >356 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510091![]() (WO2021250648, Example 43) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | >356 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510096![]() (WO2021250648, Example 48) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | >359 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510095![]() (WO2021250648, Example 47) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | >359 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510051![]() (N-{(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 439 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510060![]() (N-{(1 S)-1-Cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethy...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 539 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510079![]() (WO2021250648, Example 31) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 606 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510080![]() (WO2021250648, Example 32) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 690 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510055![]() (N-[(2S)-1-({(1 S)-1-Cyano-2-[(3S)-2-oxopyrrolidin-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 798 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510144![]() ((1R,2S,5S)-N-{(1R)-1-Cyano-2-[(3S)-2-oxopyrrolidin...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 844 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510056![]() (N-{1-Cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-N2-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 917 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510050![]() (N-{(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 1.08E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510076![]() (WO2021250648, Example 28) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 1.79E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510072![]() (WO2021250648, Example 24) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 1.93E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510077![]() (WO2021250648, Example 29) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 2.23E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510075![]() (WO2021250648, Example 27) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 4.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510118![]() (WO2021250648, Example 70) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | 6.95E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510123![]() ((2S,4R)-4-tert-Butyl-N-{(1S)-1-cyano-2-[(3S)-2-oxo...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | >8.16E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510078![]() (WO2021250648, Example 30) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | >1.08E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510055![]() (N-[(2S)-1-({(1 S)-1-Cyano-2-[(3S)-2-oxopyrrolidin-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 4.31E+4 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510060![]() (N-{(1 S)-1-Cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethy...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 6.33E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM496902![]() (PF-07321332 | WO2021250648, Example 13 | science.a...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | Purchase PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 75 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510077![]() (WO2021250648, Example 29) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 2.81E+4 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510081![]() (WO2021250648, Example 33) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >333 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510085![]() (WO2021250648, Example 37) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >3.33E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510088![]() (WO2021250648, Example 40) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >333 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510125![]() (3-Methyl-N-(trifluoroacetyl)-L-valyl-(4R)-N-{(1 S)...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 85 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510127![]() (Methyl {(2S)-1-[(1R,2S,5S)-2-({(1S)-1-cyano-2-[(3S...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 80 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510054![]() (N-[(2S)-1-({(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin-3...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 279 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510059![]() (N2-[(4-Bromo-1-ethyl-3-methyl-1H-pyrazol-5-yl)carb...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 4.78E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510082![]() (WO2021250648, Example 34) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >333 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510091![]() (WO2021250648, Example 43) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >333 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510095![]() (WO2021250648, Example 47) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >3.33E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510120![]() (WO2021250648, Example 72) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 1.35E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510121![]() (WO2021250648, Example 73) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 2.03E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510138![]() ((1R,2S,5S)-N-{(1 S)-1-Cyano-2-[(3S)-2-oxopyrrolidi...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 571 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510127![]() (Methyl {(2S)-1-[(1R,2S,5S)-2-({(1S)-1-cyano-2-[(3S...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 98 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510144![]() ((1R,2S,5S)-N-{(1R)-1-Cyano-2-[(3S)-2-oxopyrrolidin...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 9.19E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510053![]() (N-[(2S)-1-({(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin-3...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >3.33E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510057![]() (N-{1-Cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-N2-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 970 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510063![]() (N-[(2S)-1-({(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin-3...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 360 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510065![]() (N-[(2S)-1-({(1S)-1-Cyano-2-[(3S)-2- oxopyrrolidin-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >333 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510084![]() (WO2021250648, Example 36) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 1.03E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510087![]() (WO2021250648, Example 39) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >3.33E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510117![]() (WO2021250648, Example 69) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >2.67E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510118![]() (WO2021250648, Example 70) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 4.09E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510146![]() ((1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 1.74E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510048![]() ((1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 246 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510050![]() (N-{(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 7.52E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510066![]() (N-[(2S)-1-({(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin-3...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >333 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510094![]() (WO2021250648, Example 46) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >3.33E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510122![]() (WO2021250648, Example 74) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >3.33E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510071![]() (N-[(2S)-1-({(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin-3...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >333 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510072![]() (WO2021250648, Example 24) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 6.30E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510075![]() (WO2021250648, Example 27) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 4.49E+4 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510078![]() (WO2021250648, Example 30) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 9.37E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510086![]() (WO2021250648, Example 38) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >333 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM509848![]() (US11124497, Compound 361) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 2.68E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510119![]() (WO2021250648, Example 71) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 4.99E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510123![]() ((2S,4R)-4-tert-Butyl-N-{(1S)-1-cyano-2-[(3S)-2-oxo...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >1.00E+5 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510128![]() (N-(Trifluoroacetyl)-L-valyl-(4R)-N-{(1S)-1-cyano-2...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 158 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510139![]() ((1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 11 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510051![]() (N-{(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 6.74E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510067![]() (N-[(2S)-1-({(1 S)-1-Cyano-2-[(3S)-2-oxopyrrolidin-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >333 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510068![]() (N-[(2S)-1-({(1 S)-1-Cyano-2-[(3S)-2-oxopyrrolidin-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >333 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510074![]() (WO2021250648, Example 26) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >1.00E+5 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510079![]() (WO2021250648, Example 31) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 4.07E+4 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510092![]() (WO2021250648, Example 44) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >333 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510126![]() ((1R,2S,5S)-N-{(1 S)-1-Cyano-2-[(3S)-2-oxopyrrolidi...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 2.74E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510129![]() ((1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3R)-5-hydroxy-2-oxo...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 690 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510133![]() ((1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3R)-2,5-dioxopyrrol...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 334 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510135![]() (WO2021250648, Example 87) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 230 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510145![]() ((1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 82 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM496896![]() (WO2021250648, Example 4 | science.abl4784, 2) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 1.36E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510070![]() (N-[(2S)-1-({(1 S)-1-Cyano-2-[(3S)-2- oxopyrrolidin...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >333 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510073![]() (WO2021250648, Example 25) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 3.70E+4 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510076![]() (WO2021250648, Example 28) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 7.26E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510083![]() (WO2021250648, Example 35) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 3.56E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510089![]() (WO2021250648, Example 41) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >333 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510096![]() (WO2021250648, Example 48) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >3.33E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510098![]() (WO2021250648, Example 50) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 3.95E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510123![]() ((2S,4R)-4-tert-Butyl-N-{(1S)-1-cyano-2-[(3S)-2-oxo...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 551 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510136![]() ((1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 50 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510137![]() ((1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 40 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510056![]() (N-{1-Cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-N2-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 5.75E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM509871![]() (US11124497, Compound 405) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 2.09E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510064![]() (N-[(2S)-1-({(1S)-1- Cyano-2-[(3S)-2-oxopyrrolidin-...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >2.53E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510080![]() (WO2021250648, Example 32) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 4.90E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510090![]() (WO2021250648, Example 42) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | >333 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510093![]() (WO2021250648, Example 45) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 6.42E+3 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510134![]() ((1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 237 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510140![]() (3-Methyl-N-[(4-methylphenyl)acetyl]-L-valyl-(4R)-N...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 19 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510141![]() ((1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 882 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Replicase polyprotein 1ab (2019-nCoV) | BDBM510142![]() ((1R,2S,5S)-N-{(1 S)-1-Cyano-2-[(3S)-2-oxopyrrolidi...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL DrugBank GoogleScholar | PC cid PC sid UniChem | WIPO | n/a | n/a | n/a | n/a | 379 | n/a | n/a | n/a | n/a |
Pfizer Inc. WIPO | Assay Description The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay... | WIPO WO2021250648A1 (2021) | |||||||||||
More data for this Ligand-Target Pair |